Records 1-30 (of 255 Records) |
Query Trace: Pregnancy[original query] |
---|
The Importance of Vaccination, Variants and Time Point of SARS-CoV-2 Infection in Pregnancy for Stillbirth and Preterm Birth Risk: An Analysis of the CRONOS Register Study. Iannaccone Antonella, et al. Journal of clinical medicine 2024 0 0. (6) |
Global Transcriptomic Analysis of Placentas from Women with Gestational SARS-CoV-2 Infection during the Third Trimester of Pregnancy. Yiqun Tang et al. Int J Mol Sci 2024 2 (3) |
Gene crosstalk between COVID-19 and preeclampsia revealed by blood transcriptome analysis. Chu Yijing, et al. Frontiers in immunology 2024 0 0. 1243450 |
mRNA SARS-CoV-2 Vaccination Before vs During Pregnancy and Omicron Infection Among Infants. Orlanda Goh et al. JAMA Netw Open 2023 11 (11) e2342475
From the abstract: "s maternal vaccination associated with a lower risk of infection with Omicron SARS-CoV-2 variants, including XBB, among infants up to 6 months of age? In this national population-based cohort study of 7292 infants aged 6 months or younger in Singapore, the estimated vaccine effectiveness in infants against Omicron SARS-CoV-2 variants, including XBB, from maternal messenger RNA (mRNA) SARS-COV-2 vaccination was 42%. A lower risk of infection was only found in infants when the vaccine was administered during pregnancy. "
|
Pre-Delta, Delta, and Omicron Periods of the Coronavirus Disease 2019 (COVID-19) Pandemic and Health Outcomes During Delivery Hospitalization. Carlson Jeffrey, et al. Obstetrics and gynecology 2023 0 0. |
Genome-wide neonatal epigenetic changes associated with maternal exposure to the COVID-19 pandemic. Kocher Kristen, et al. BMC medical genomics 2023 0 0. (1) 268 |
Relationship between serum lactate dehydrogenase levels and prognosis in patients infected with omicron and delta variants of COVID-19: A cross-sectional study. Ostadi Fatemeh, et al. Toxicology reports 2023 0 0. 368-373 |
The clinical characteristics of COVID-19 omicron variant infection in pregnant women and their neonates. Liu Li-Li, et al. Frontiers in medicine 2023 0 0. 1229794 |
Reduced maternal immunity and vertical transfer of immunity against SARS-CoV-2 variants of concern with COVID-19 exposure or initial vaccination in pregnancy. Boelig Rupsa C, et al. Frontiers in immunology 2023 0 0. 1216410 |
Effectiveness of COVID-19 vaccination during pregnancy by circulating viral variant. Zerbo Ousseny, et al. AJOG global reports 2023 0 0. (4) 100264 |
Delta Variant Neutralizing Antibody Response following Maternal COVID19 Vaccination. Craig Amanda M, et al. American journal of infection control 2023 0 0. |
Predicting adverse outcomes in pregnant patients positive for SARS-CoV-2: a machine learning approach- a retrospective cohort study. Young Dylan, et al. BMC pregnancy and childbirth 2023 0 0. (1) 553 |
Commentary: Predicting adverse outcomes in pregnant patients positive for SARS-CoV-2 by a machine learning approach. Salmeri Noemi, et al. BMC pregnancy and childbirth 2023 0 0. (1) 554 |
SARS-CoV-2 Covid-19 Infection During Pregnancy and Differential DNA Methylation in Human Cord Blood Cells From Term Neonates. Urday Pedro, et al. Epigenetics insights 2023 0 0. 25168657231184665 |
Single-cell analysis reveals transcriptomic and epigenomic impacts on the maternal-fetal interface following SARS-CoV-2 infection. Gao Lin, et al. Nature cell biology 2023 0 0. |
The microbiota of pregnant women with SARS-CoV-2 and their infants. Leftwich Heidi K, et al. Microbiome 2023 0 0. (1) 141 |
Safety and Effectiveness of Maternal COVID-19 Vaccines Among Pregnant People and Infants. Fleming-Dutra Katherine E, et al. Obstetrics and gynecology clinics of North America 2023 0 0. (2) 279-297 |
Outcomes of pregnant women exposed to Sotrovimab for the treatment of COVID-19 in the BA.1 Omicron predominant era (PRESTO). Tuan Jessica J, et al. BMC infectious diseases 2023 0 0. (1) 258 |
Pregnancy-specific responses to COVID-19 revealed by high-throughput proteomics of human plasma. Nardhy Gomez-Lopez et al. Communications medicine 2023 4 (1) 48
Herein, we profile the plasma proteome of pregnant and non-pregnant COVID-19 patients and controls and show alterations that display a dose-response relationship with disease severity; yet, such proteomic perturbations are dampened during pregnancy. In both pregnant and non-pregnant state, the proteome response induced by COVID-19 shows enrichment of mediators implicated in cytokine storm, endothelial dysfunction, and angiogenesis.
|
miRNAs as a Potential Biomarker in the COVID-19 Infection and Complications Course, Severity, and Outcome. Jankovic Milena, et al. Diagnostics (Basel, Switzerland) 2023 0 0. (6) |
End-Stage Kidney Disease Resulting from Atypical Hemolytic Uremic Syndrome after Receiving AstraZeneca SARS-CoV-2 Vaccine: A Case Report. Tawhari Mohammed, et al. Vaccines 2023 0 0. (3) |
Maternal third dose of BNT162b2 mRNA vaccine and risk of infant COVID-19 hospitalization M Lipshhuetz et al, Nature Medicine, March 23, 2023
Compared to the second dose, the third dose was associated with reduced infant hospitalization with estimated effectiveness of 53% (95% CI: 36–65%). Greater protection was associated with a shorter interval between vaccination and delivery. A third maternal dose during pregnancy reduced the risk of infant hospitalization for COVID-19 during the first 4?months of life, supporting clinical and public health guidance for maternal booster vaccination to prevent infant COVID-19 hospitalization.
|
Covid-19 variants of concern and pregnancy. Stock Sarah J, et al. BMJ medicine 2023 0 0. (1) e000151 |
Severe COVID-19 during pregnancy in Sweden, Norway, and Denmark. Örtqvist Anne K, et al. Acta obstetricia et gynecologica Scandinavica 2023 0 0. |
Impact of ACE2 and TMPRSS2 Expression in Patients With Preeclampsia. Park Ji Eun, et al. In vivo (Athens, Greece) 2023 0 0. (2) 625-633 |
Impact of variants of SARS-CoV-2 on obstetrical and neonatal outcomes. Poisson M, et al. Journal of gynecology obstetrics and human reproduction 2023 0 0. 102566 |
Fetal cell microchimerism and susceptibiltiy to COVID-19 disease in women. Cirello Valentina, et al. Infection 2023 0 0. 1-8 |
Maternal SARS-CoV-2 vaccination and infant protection against SARS-CoV-2 during the first six months of life. Zerbo Ousseny, et al. Nature communications 2023 0 0. (1) 894 |
Estimated Effectiveness of Postpartum Maternal Messenger RNA COVID-19 Vaccination Against Delta and Omicron SARS-CoV-2 Infection and Hospitalization in Infants Younger Than 6 Months SCJ Jorgenson et al, JAMA Pediatrics, February 27, 2023
Postpartum maternal COVID-19 vaccination was moderately effective against Delta infection in infants younger than 6 months but conferred little protection against Omicron. Indirect comparisons suggest postpartum maternal COVID-19 vaccination may be inferior to maternal vaccination during pregnancy, particularly against Omicron.
|
Patterns of Diverse and Changing Sentiments Towards COVID-19 Vaccines: A Sentiment Analysis Study Integrating 11 Million Tweets and Surveillance Data Across over 180 Countries. Wang Hanyin, et al. Journal of the American Medical Informatics Association : JAMIA 2023 0 0. |
Disclaimer: Articles listed in the Public Health
Knowledge Base are selected by the CDC Office of Public Health
Genomics to provide current awareness of the literature and news.
Inclusion in the update does not necessarily represent the views of
the Centers for Disease Control and Prevention nor does it imply
endorsement of the article's methods or findings. CDC and DHHS assume
no responsibility for the factual accuracy of the items presented. The
selection, omission, or content of items does not imply any
endorsement or other position taken by CDC or DHHS. Opinion, findings
and conclusions expressed by the original authors of items included in
the update, or persons quoted therein, are strictly their own and are
in no way meant to represent the opinion or views of CDC or DHHS.
References to publications, news sources, and non-CDC Websites are
provided solely for informational purposes and do not imply
endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 18, 2024
- Content source: